Onco Actu du 7 octobre 2016

	2. Etiologie
Working night shifts unlikely to increase breast cancer risk [Cancer Research UK] The researchers found that the incidence of breast cancer was essentially the same whether someone did no night shift work at all or did night shift work for several decades – the combined relative risks taking all 10 studies together were 0.99 for any night shift work, 1.01 for 20 or more years of night shift work, and 1.00 for 30 or more years night shift work.
Breast cancer risk 'not increased' by night shifts [BBC News] In 2007, a World Health Organization committee said shift work "probably" had a link to breast cancer, based on studies of animals and people. But this new work by leading UK cancer experts looked at data on 1.4m women and found there was no association with night shift work.
	3.1.1 Tabac - e-cigs
For less toxic e-cigarettes, skip the strawberry [Reuters] Researchers tested vapor released by a variety of devices filled with some popular e-cigarette flavors – tobacco, pina colada, menthol, coffee and strawberry – to compare levels of chemicals known to cause inflammation and cell damage. They also looked at how much these chemicals appeared in tobacco smoke and in smoke-free air.
	3.3 Prévention - Vaccins
As Parents Consider the HPV Vaccine, the Message Matters [Cancer Research Catalyst] Malo was surprised to discover that even parents who told the researchers that they were considering not having their children vaccinated against HPV said they could be persuaded by some of the messages.
	4.1 Dép., diag. & prono. - Prostate
No, the PSA test probably didn’t save Ben Stiller’s life [Respectful Insolence] It’s understandable why Stiller feels this way and believes this. Also, in fairness, one aspect of Stiller’s case that tends to be in his favor is how young he is. Prostate cancer before the age of 50 is very uncommon. Be that as it may, it is a maddeningly intuitive notion that early detection always saves lives.
	4.7 Dép., diag. & prono. - Col de l'utérus
Cervical screening every 10 years for healthy women is 'safe' [NHS Choices] Testing for HPV has already been incorporated into the NHS Cervical Screening Programme. A further UK-based pilot study would be required if the length of time between screening for certain low-risk women was to be extended in the UK.
	4.9 Dép., diag. & prono. - Sein
Do You Need Extra Screening For Breast Cancer? The Picture Is Blurry [NPR] Many of those women may be wondering about extra screening after receiving notification letters saying that their mammogram was clean, but that their dense breasts put them at higher risk of cancer.
	5. Traitements
Avelumab Induces Sustained Tumor Responses in Some Patients with Rare Skin Cancer [NCI] In the phase II trial, 32% of patients with metastatic Merkel cell carcinoma that had returned after earlier treatment experienced partial or complete shrinkage of their tumors when treated with the new drug. Among patients whose tumors shrank, more than 90% sustained this response for at least 6 months.
Daratumumab for Myeloma [Now@NEJM] The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide and dexamethasone alone, at a cost of more frequent neutropenia and infusion reactions.
	5.12 Immunothérapies
For cancer patients, newest treatments force the ultimate decision, with no room for error [STAT] Immunotherapy treatments have transformed care for certain forms of cancer, and they have shown promise even for colon cancer, which Lefebvre was diagnosed with in 2013. But the devil is in cancer’s details, and Lefebvre is especially bedeviled by hers.
	5.2.1 Pharma - Partenariats
CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration [Cancer Research UK] CRT will receive development milestones and royalties on sales of products from the collaboration, and has the right to develop the molecules further if GlaxoSmithKline declines to do so.
	5.4 Traitements - Economie
How Ariad Pharma Used a Safety Problem to Jack Up a Cancer Drug's Price [The Street] Iclusig was now a niche drug for CML, but instead of reducing its price tag to reflect less benefit overall for CML patients, Ariad embarked on a series of massive price increases.
	5.6 ESMO
Myriad Announces Four Poster Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting [Myriad] New Data Support the Utility of the Company's Advanced Companion Diagnostic Tests.
ESMO 2016 Press Release: Improving Cancer Screening Participation Should be a Priority [ESMO] Early diagnosis of cancer is linked to better survival rates. Unfortunately, participation rates for cancer screening worldwide are low even when screening programmes are free. The ESMO 2016 Congress is showcasing five studies on this important area of cancer management which look at alternative ways to overcome barriers and improve screening rates.
	5.6.2 ESMO - Divers
ESMO 2016 Press Release: High response rate in phase I/II paediatric brain cancer trial sets stage for combination therapy with higher response and lower toxicity [ESMO] Up to 10% of paediatric low-grade gliomas have the BRAF V600 mutation. Today researchers reported the phase I and phase II trial results of dabrafenib, a selective inhibitor of mutant protein. The study included 32 patients aged one to 16 years with BRAF V600-mutant low-grade glioma, of whom 15 participated in the phase I trial and 17 were in the phase II trial.
	5.6.4 ESMO - Poumon
ESMO 2016 Press Release: Neoadjuvant Immunotherapy Prior to Surgery is Safe and Feasible in Early Lung Cancer [ESMO] The study included 20 patients who had a tumour biopsy taken. They then received two doses of nivolumab at four and two weeks prior to surgical resection of the tumour.
	5.6.5 ESMO - Mélanome & Peau
ESMO 2016 Press Release: Thousands of melanoma patients in Europe have no access to new life saving drugs [ESMO] The survey showed that in Western Europe 70% of patients were treated with innovative medicines, while in Eastern Europe less than 10% of patients had access to the latest treatment recommended by current European Guidelines (ESMO, EORTC/EADO).
Thousands of European melanoma patients lack access to new drugs [Reuters] Out of an estimated 19,250 metastatic melanoma patients treated annually, 5,228 or 27 percent do not have access to new drugs that are now recommended under European treatment guidelines.
	5.6.6 ESMO - Sein
Pilot project provides a snapshot of effectiveness of Pfizer’s PARP contender talazoparib [EndPoints] The big show this weekend, though, will be reserved for Tesaro and Clovis Oncology, which both have closely-watched PARPs lining up for potential approvals.
	6. Lutte contre les cancers
MAP conference 2016: proving the potential of personalised medicine [Cancer Research UK] “There is a major gap between our understanding of cancer biology and our basic approach to patient management,” said Professor Charles Swanton, a Francis Crick Institute scientist, part-funded by Cancer Research UK and one of the conference founders. This isn’t through lack of trying, but it does reflect the fact that more needs to be added to the ever-growing cancer knowledge pot. And key to this is data; lots of it.
	6.10.1 Politiques (USA)
Exclusive: U.S. lawmakers to investigate funding of WHO cancer agency [Reuters] An aide to the U.S. House Committee on Oversight and Government Reform told Reuters that National Institutes of Health officials have agreed to give an in-person briefing to the committee after questions were raised by lawmakers over its grants to the International Agency for Research on Cancer (IARC), a semi-autonomous part of the WHO based in Lyon, France.
	6.7.2 Applis
It’s not just apps. Health care innovation requires true communication [STAT] Smartphone apps, wearables, medical devices, and other gadgets that promise to improve health are being developed at an ever faster pace. These developments often come from companies and startups that are relatively new to health care.